NAV

Triciribine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Triciribine
DrugBank Accession Number
DB12405
Background

Triciribine has been used in trials studying the treatment of Leukemia, Ovarian Cancer, HER2/Neu Negative, Breast Adenocarcinoma, and Stage IV Breast Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 320.309
Monoisotopic: 320.123303019
Chemical Formula
C13H16N6O4
Synonyms
  • Pentaazacentopthylene
  • TCN
  • Triciribina
  • Triciribine
  • Triciribinum
External IDs
  • NSC-154020
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Triciribine phosphateNot AvailableNot AvailableNot applicable

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as glycosylamines. These are compounds consisting of an amine with a beta-N-glycosidic bond to a carbohydrate, thus forming a cyclic hemiaminal ether bond (alpha-amino ether).
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Glycosylamines
Alternative Parents
Pentoses / Pyrrolo[2,3-d]pyrimidines / Pyrrolo[3,4-d]pyridazines / Pyrimidines and pyrimidine derivatives / Pyridazines and derivatives / Imidolactams / Substituted pyrroles / Tetrahydrofurans / Heteroaromatic compounds / Amidrazones
show 7 more
Substituents
Alcohol / Aromatic heteropolycyclic compound / Azacycle / Carboxylic acid amidrazone / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam / Monosaccharide / N-glycosyl compound / Organic nitrogen compound
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
nucleoside analogue (CHEBI:65310)
Affected organisms
Not Available

Chemical Identifiers

UNII
2421HMY9N6
CAS number
35943-35-2
InChI Key
HOGVTUZUJGHKPL-HTVVRFAVSA-N
InChI
InChI=1S/C13H16N6O4/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(22)8(21)6(3-20)23-13/h2,4,6,8-9,13,20-22H,3H2,1H3,(H2,14,17)/t6-,8-,9-,13-/m1/s1
IUPAC Name
(2R,3R,4S,5R)-2-{5-amino-7-methyl-2,6,7,9,11-pentaazatricyclo[6.3.1.0^{4,12}]dodeca-1(12),3,5,8,10-pentaen-2-yl}-5-(hydroxymethyl)oxolane-3,4-diol
SMILES
CN1N=C(N)C2=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C3=C2C1=NC=N3

References

General References
Not Available
PubChem Compound
65399
PubChem Substance
347828651
ChemSpider
58865
BindingDB
50369528
ChEBI
65310
ChEMBL
CHEMBL331237
ZINC
ZINC000003808299
PDBe Ligand
ZJB
Wikipedia
Triciribine
PDB Entries
5aqg

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHematological Malignancy / Leukemias1
1, 2TerminatedTreatmentBreast Adenocarcinoma / Breast Cancer Stage IIIc / Breast Cancer, Stage IIIB / Carcinoma Breast Stage IV / Estrogen Receptor Positive / HER2 negative / Recurrent Breast Carcinoma / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
1, 2TerminatedTreatmentOvarian Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.91 mg/mLALOGPS
logP-1.4ALOGPS
logP-1.5Chemaxon
logS-1.6ALOGPS
pKa (Strongest Acidic)12.46Chemaxon
pKa (Strongest Basic)8.33Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area144.47 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity90.56 m3·mol-1Chemaxon
Polarizability31.22 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0901000000-df45b8c236a426d1165d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dr-0709000000-a42e0bcd1daa8636adb7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0926000000-49a371b858ca4766c5e5
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-052r-4960000000-572d1ca0e60f9e0138b5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kr-1940000000-d1ca4d2d0fe87cc3803b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0940000000-6505ef43d1529104a7fa
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-186.4064743
predicted
DarkChem Lite v0.1.0
[M-H]-172.23465
predicted
DeepCCS 1.0 (2019)
[M+H]+185.3977743
predicted
DarkChem Lite v0.1.0
[M+H]+174.63022
predicted
DeepCCS 1.0 (2019)
[M+Na]+185.9334743
predicted
DarkChem Lite v0.1.0
[M+Na]+180.54276
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:15 / Updated at September 28, 2023 05:47